GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Inventories, Finished Goods

HLTRF (HLS Therapeutics) Inventories, Finished Goods : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Inventories, Finished Goods?


HLS Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for HLS Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Inventories, Finished Goods Chart

HLS Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HLS Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HLS Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

HLS Therapeutics Headlines

From GuruFocus

Q3 2020 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q4 2020 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2022 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2021 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

HLS Therapeutics Inc. - Special Call Transcript

By GuruFocus Research 02-13-2024

Q4 2021 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2023 HLS Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024